Five months after announcing its intentions to gather genome sequences from 2 million people, pharmaceutical giant AstraZeneca has selected geneticist David Goldstein to head up the task.
View Full Article
Create a Web Account
If you are an ACM member, Communications subscriber, Digital Library subscriber, or use your institution's subscription, please set up a web account to access premium content and site features. If you are a SIG member or member of the general public, you may set up a web account to comment on free articles and sign up for email alerts.